On March 18, 2026 Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, reported that the Company will present new clinical trial data at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, to be held April 17-22 in San Diego, California, and at the American Academy of Neurology (AAN) Annual Meeting, to be held April 18-22 in Chicago, Illinois. Both conferences will feature clinical data on DOC1021 (dubodencel), a first-in-class, patient-derived double-loaded dendritic cell investigational therapy, with AACR (Free AACR Whitepaper) focusing on pancreatic ductal adenocarcinoma and AAN on glioblastoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Presenting data at both of these conferences underscores the breadth and potential impact of DOC1021 across some of the most challenging cancers," said Jay Hartenbach, President and COO of Diakonos Oncology. "The AACR (Free AACR Whitepaper) presentation provides updated data from our ongoing pancreatic cancer study, and the AAN presentation will mark the first report of results from our expanded access program in glioblastoma. These clinical data continue to validate DOC1021’s novel mechanism, which leverages a patient’s full complement of tumor antigens to drive robust immune responses against malignancy. We look forward to sharing these new results and advancing this first‑in‑class therapy to improve outcomes for patients with pancreatic cancer and glioblastoma, both of which are marked by poor prognosis and significant unmet need."

Details on the AACR (Free AACR Whitepaper) poster presentation are outlined below:

Title: Clinical and Immunologic Assessment of DOC1021 Dendritic Cell Therapy in Resectable or Borderline Resectable Pancreatic Cancer
Authors: Konduri, V., Trivedi, A., Liu, W., Namekar, M., Ernste, K., Wilson, G. G., Duus, E. M., Armaghany, T., Makawita, S. U., Camp, E. R., Van Buren, G., Aguilar, L. K., Musher, B. L., and Decker, W. K.
Abstract Number/Poster Number: abstract #CT093 / poster #24 in Poster Section 51
Session Name: Phase I Clinical Trials in Progress
Presentation Date/Time: Monday, April 20, from 9:00 AM–12:00 PM PT.

Details on the AAN poster presentation are outlined below:

Title: DOC1021 Cell-based Immunotherapy in Combination with Standard Chemoradiation for Adjuvant Therapy of Glioblastoma: Early Results from an Expanded Access Protocol of a Phase I Trial
Authors: Zhu, J‑J., Esquenazi‑Levy, Y., Hsu, S., Vu, M., Zvavanjanja, R. C., Trivedi, A., Liu, W., Namekar, M., Ernste, K., Tandon, N., Schumann, E. H., Duus, E. M., Aguilar, L. K., Georges, J. F., Konduri, V., and Decker, W. K.
Abstract Number/Poster Number: abstract #3099 / poster #010 in Neighborhood 6
Session Name: P11: Neuro-oncology: Neurosurgery and Immunotherapy Trials
Presentation Date/Time: Wednesday, April 22, from 11:45 AM–12:45 PM CT.

About DOC1021
DOC1021 is a first-in-class, patient-derived double-loaded dendritic cell therapy that combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is made with a patient’s dendritic cells combined with mRNA and proteins prepared from freshly obtained patient tumor specimens.

The unique double-loading approach, a physiologic mimic of viral infection, unlocks a synergistic and exponentially more powerful tumor killing response that permits complete targeting of the total cancer antigen pool. Moreover, the approach does not require any molecular modification or genetic engineering of the patient’s immune cells and does not require preconditioning chemotherapy or high dose IL-2 for administration. DOC1021 is designed for outpatient administration and broad access via community cancer centers.

Diakonos currently has two actively enrolling clinical trials with DOC1021, a Phase 1 pancreatic cancer study (NCT04157127) and a Phase 2 glioblastoma (GBM) study (NCT06805305). Diakonos received Fast Track designation from the FDA for both the GBM and pancreatic cancer programs in October 2023 and May 2024, respectively. The company also received Orphan Drug Designation for the GBM program in January 2024. A refractory melanoma Phase 1/2 study with DOC1021 (NCT07288112) will be initiated early this year with the facilitation and support of the Cancer Prevention and Research Institute of Texas (CPRIT).

(Press release, Diakonos Oncology, MAR 18, 2026, View Source [SID1234663709])

On March 18, 2026 Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, reported that Seth Lederman, MD, Chief Executive Officer, will deliver a company presentation at BIO-Europe Spring 2026, being held March 23-25, 2026, in Lisbon, Portugal.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Company Presentation Details

Date and Time: Tuesday, March 24, 2026, 1:30-1:45 p.m. WET
Location: Presentation Theatre A
Presenter: Seth Lederman, MD, Chief Executive Officer

(Press release, TONIX Pharmaceuticals, MAR 18, 2026, View Source [SID1234663705])

On March 18, 2026 Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, reported upcoming presentations at the 2026 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting and NextGen Biomed 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The AACR (Free AACR Whitepaper) Annual Meeting will take place April 17–22, 2026 in San Diego, California, and NextGen Biomed 2026 will be held March 24–26, 2026 in London, United Kingdom.

Presentation Details:

AACR Poster Session (abi-suva)
Session title: Phase I Clinical Trials
Title: Immunogenicity of the therapeutic HPV16-specific cancer vaccine abipapogene suvaplasmid (VB10.16) in combination with pembrolizumab given as 1L treatment for HPV16+ PD-L1+ r/m oropharyngeal cancer: preliminary results from phase 1 of the VB-C-03 trial

Location: Poster Section 50
Poster Board Number: 9
Date: April 21, 2026
Time: 09:00 AM – 12:00 PM PDT

NextGen Biomed Presentation (VB10.NEO)
Title: VB10.NEO: The Journey of a Clinically Validated Individualized Cancer Therapy from Tumour Biopsy to Vaccine Administration

Date: March 24, 2026
Time: 11:40-12:00 GMT

NextGen Biomed Presentation (Tolerance):
Title: Development Of APC-Targeted Antigen-Specific Immune Tolerance Therapies For Autoimmune Diseases

Date: March 25, 2026
Time: 12:00-12:25 GMT

The presentation slides will be available after the presentations at the
Company’s webpage:
View Source

(Press release, Nykode Therapeutics, MAR 18, 2026, View Source [SID1234663704])

On March 18, 2026 Kupando, a pioneering biopharmaceutical company developing a TLR 4/7 agonist that stimulates innate immunity and induces trained immunity for use in oncology and infectious diseases, reported that it has secured an additional €10 million in Series A financing. This latest investment brings Kupando’s total Series A funding to €23 million.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The investment was again led by Remiges Ventures, co-led by LifeCare Partners, with additional investments by all other existing investors, among them Brandenburg Kapital, High-Tech Gründerfonds and Ventura Biomed Investors. Carma Fund joined as a new investor. The proceeds will be used to fund the Phase 1b clinical study of Kupando’s lead candidate, KUP101, in advanced solid tumors and to accelerate its preclinical programs in infectious diseases.

Kupando’s disruptive approach harnesses the power of innate immune stimulation and induction of trained innate immunity by dual Toll-Like Receptor (TLR) agonists. Its lead candidate, KUP101, is a differentiated dual TLR 4 and 7 agonist with a robust preclinical profile approaching clinical development. KUP101 is ideally suited for the systemic treatment of solid tumors (tissue agnostic), and the prevention and treatment of infectious diseases, including antimicrobial-resistant infections. Its AMR program is being sponsored by the Federal Ministry of Research, Technology and Space.

"We are incredibly grateful for the continued strong support from our existing investors and excited to welcome Carma Fund to the Kupando family," said Johanna Holldack, MD, Founder and CEO of Kupando. "This additional funding is a testament to the potential of our innovative dual TLR agonist platform and will be instrumental in advancing KUP101 into clinical studies for solid tumors and accelerating our crucial work in infectious diseases. Our mission is to leverage the natural resilience of the innate immune system to deliver truly transformative therapies for patients in critical need."

New investor Martin Raditsch, PhD, Managing Partner of Carma Fund, commented, "Kupando’s unique approach to leveraging innate immunity holds immense promise across oncology and infectious diseases. This successful funding round, especially in the current challenging financial climate, underscores the confidence we, as investors, have in Kupando’s science, team, and potential to deliver impactful solutions for unmet medical needs."

Kazuhiko Nonomura, PhD, Partner of Remiges Ventures and member of Kupando’s Advisory Board, added, "Remiges Ventures is proud to continue leading the investment in Kupando. We believe Kupando’s dual TLR 4 and 7 agonist technology, particularly KUP101, has the potential to redefine treatment paradigms in both cancer and infectious diseases. We are excited to see the company transition to the clinical stage and unlock the full potential of its pipeline."

Kupando was founded by its CEO Johanna Holldack, MD, driven by the natural resilience observed in animals relying solely on innate immunity. Recognizing the historically undervalued yet critical role of this system, especially with the new understanding of innate and trained immunity, Kupando has made it the core of its therapeutic approach.

(Press release, Kupando, MAR 18, 2026, View Source [SID1234663703])

On March 18, 2026 Ipsen (Euronext: IPN; ADR: IPSEY) reported the presentation of new preclinical data across multiple early development programs currently in Phase I clinical trials, at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) congress. These latest data include an oral presentation for T cell activator (TCA) IPN01203 to be presented during the coveted New Drugs on the Horizon program session, highlighting the differentiated mode of action, activating Vβ6/Vβ10 T cells. These latest preclinical data will expand the growing evidence base, reinforcing the first-in-class potential of IPN01203 to improve outcomes where there are significant unmet needs for people living with solid tumors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Additionally, Ipsen revealed ITGA2 as the novel target for innovative antibody-drug conjugate (ADC) IPN60300, now in active Phase I evaluation. Preclinical findings showed pronounced over-expression of ITGA2 across multiple solid tumors—including pancreatic, gastric and colorectal cancers—with clear differential expression when compared to normal tissues. These results confirmed that IPN60300 binds specifically and with high affinity to ITGA2, enabling efficient internalization and accumulation of the exatecan payload. Further preclinical tumor model data showed dose-dependent anti-tumor activity and favorable tolerability, suggesting a promising first-in-class therapy with the potential to improve clinical outcomes.

"These data presented at AACR (Free AACR Whitepaper) exemplify our approach to early science, showcasing how we are harnessing precision immuno-modulation backed by the strength of preclinical data to advance next generation therapies where there are the highest unmet needs," said Mary Jane Hinrichs, SVP Early Development, Ipsen. "It’s a privilege to see the growing transformative potential of these new modalities, paving the way for potential best- and first-in-class impact for people living with cancer."

Underscoring the strength and promise of Ipsen’s precision medicine approach, IPN01203 and IPN60300 combine precision targeting with innovative mechanisms of action with the aim of delivering strength of efficacy where few other treatments exist.

About IPN01203

IPN01203 is a first-in-class T cell activator which selectively activates a group of Vβ6 T cells through the TCR and IL-15R pathways, enhancing their ability to recognize and target tumors. IPN01203 was generated by Marengo’s Selective T Cell Activation Repertoire (STAR) platform, a multi-specific fusion protein library that targets specific TCR Vβ variants fused to different co-stimulate moieties to develop potent T cell activators. A Phase I/II dose escalation and expansion trial is ongoing.

About IPN60300

IPN60300 is a first-in-class antibody-drug conjugate targeting the novel tumor antigen ITGA2 known to be overexpressed in many solid tumors, including pancreatic, gastric and colorectal cancers. This novel tumor antigen was identified using Foreseen’ Biotechnology’s high throughput, integrated translational proteomics, and artificial intelligence (AI)-powered screening platforms. Comprised of an ITGA2-targeting antibody, exatecan payload and innovative linker from Escugen Biotechnology’s EZWi-Fit, IPN60300 is optimally designed to allow for a wide therapeutic index, with potential for improved efficacy over standard of care as well as a favorable safety profile. A Phase I/II dose escalation and expansion trial is ongoing.

(Press release, Ipsen, MAR 18, 2026, View Source [SID1234663702])